Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream.
BACKGROUND
Multiple treatments for squamous cell carcinoma in situ (SCCIS) of the penis have been used with variable success and morbidity. Surgery and destructive treatment modalities have significant risk of scarring, deformity, and impaired function.


OBJECTIVE
The purpose of this study was to determine whether topical imiquimod 5% cream is a potentially effective treatment for SCCIS of the penis and to qualify treatment associated morbidity.


METHODS
The case of a patient with extensive penile SCCIS is reported. The patient was treated with topical imiquimod 5%, administered daily until blistering occurred (2 cycles). Biopsy specimens were obtained to confirm tumor clearance.


RESULTS
One month after therapy was completed, no clinical or histologic evidence of residual tumor was found. Adverse effects of imiquimod included localized tenderness and erythema. No evidence of scarring, deformity, loss of function, or tumor recurrence was noted 18 months after treatment.


CONCLUSIONS
Imiquimod 5% cream may represent an alternative treatment option for SCCIS of the penis.
Schroeder
Theresa L
TL
Washington University, St. Louis, MO 63141, USA.
Sengelmann
Roberta D
RD
D000287:Administration, Topical; D000368:Aged; D000634:Aminoquinolines / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001913:Bowen's Disease / Q000188:drug therapy / Q000473:pathology; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077271:Imiquimod; D008297:Male; D009824:Ointments; D010412:Penile Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D009824:Ointments; D000077271:Imiquimod